Application 208539
- Type
- ANDA
- Sponsor
- MICRO LABS LTD
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | TICAGRELOR | TICAGRELOR | TABLET;ORAL | 60MG | No | No |
| 002 | TICAGRELOR | TICAGRELOR | TABLET;ORAL | 90MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A208539-001 | TICAGRELOR | TICAGRELOR | 60MG | TABLET / ORAL | AB | 2026-04-27 | |
| A208539-002 | TICAGRELOR | TICAGRELOR | 90MG | TABLET / ORAL | AB | 2026-04-27 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A208539-001 | AB |
| A208539-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A208539-001 | TICAGRELOR | 60MG | TABLET / ORAL | AB | 2026-04-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A208539-002 | TICAGRELOR | 90MG | TABLET / ORAL | AB | 2026-04-27 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A208539-001 | TICAGRELOR | 60MG | TABLET / ORAL | AB | 2026-04-27 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A208539-002 | TICAGRELOR | 90MG | TABLET / ORAL | AB | 2026-04-27 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A208539-001 | TICAGRELOR | 60MG | TABLET / ORAL | AB | 2026-04-27 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A208539-002 | TICAGRELOR | 90MG | TABLET / ORAL | AB | 2026-04-27 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A208539-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A208539-002 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A208539-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A208539-002 | AB | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A208539-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A208539-002 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| TICAGRELOR | TICAGRELOR | Solco Healthcare U.S., LLC | 5be5ef20-fc9f-4c3b-a482-83ffd8a3ab47 | 2025-11-11 | Boxed warning, Warnings, Adverse reactions | TICAGRELOR TICAGRELOR |
| Ticagrelor | TICAGRELOR | Alembic Pharmaceuticals Inc. | d68b79ab-3104-410e-a63f-9919a23625af | 2025-10-30 | Boxed warning, Warnings, Adverse reactions | Ticagrelor TICAGRELOR |
| Ticagrelor | TICAGRELOR | Alembic Pharmaceuticals Limited | 82f66384-e2c7-41c5-961f-384918ef58ec | 2025-10-30 | Boxed warning, Warnings, Adverse reactions | Ticagrelor TICAGRELOR |
| Ticagrelor | TICAGRELOR | Ascend Laboratories, LLC | 3225098b-3138-4aec-a866-de94c3006e8e | 2025-10-29 | Boxed warning, Warnings, Adverse reactions | Ticagrelor TICAGRELOR |
| TICAGRELOR | TICAGRELOR | AvPAK | 425024ab-e092-7a6d-e063-6294a90ae4f3 | 2025-10-29 | Boxed warning, Warnings, Adverse reactions | TICAGRELOR TICAGRELOR |
| Ticagrelor | TICAGRELOR | Changzhou Pharmaceutical Factory | 751410c1-452b-400b-a640-d31623a6fda3 | 2025-10-29 | Boxed warning, Warnings, Adverse reactions | Ticagrelor TICAGRELOR |
| Ticagrelor | TICAGRELOR | BIONPHARMA INC. | 4239fc4c-dae6-eb51-e063-6394a90a00d5 | 2025-10-28 | Boxed warning, Warnings, Adverse reactions | Ticagrelor TICAGRELOR |
| Ticagrelor | TICAGRELOR | Oryza Pharmaceuticals, Inc. | 461d810e-5b77-5e53-e063-6294a90a64b0 | 2025-10-23 | Boxed warning, Warnings, Adverse reactions | Ticagrelor TICAGRELOR |
| TICAGRELOR | TICAGRELOR | AvKARE | 40bb0fb0-2275-4df7-e063-6394a90ade2e | 2025-10-09 | Boxed warning, Warnings, Adverse reactions | TICAGRELOR TICAGRELOR |
| TICAGRELOR | TICAGRELOR | AvKARE | 32ebf046-73e4-b11b-e063-6294a90a5bf4 | 2025-04-24 | Boxed warning, Warnings, Adverse reactions | TICAGRELOR TICAGRELOR |
| Ticagrelor | TICAGRELOR | Oryza Pharmaceuticals, Inc. | 32c950bd-7f5f-a811-e063-6394a90a0080 | 2025-04-15 | Boxed warning, Warnings, Adverse reactions | Ticagrelor TICAGRELOR |
| Ticagrelor | TICAGRELOR | Mylan Pharmaceuticals Inc. | fc333c4a-ad63-4d67-a3f7-431ac469d116 | 2025-04-14 | Boxed warning, Warnings, Adverse reactions | Ticagrelor TICAGRELOR |
| TICAGRELOR | TICAGRELOR | Exelan Pharmaceuticals, Inc | eb8fb960-1f0e-40b1-9889-b02296bb3c37 | 2025-03-01 | Boxed warning, Warnings, Adverse reactions | TICAGRELOR TICAGRELOR |
| Ticagrelor | TICAGRELOR | Cipla USA Inc. | 789606e3-9efa-440c-84f1-f1c56fcbf0cd | 2025-03-01 | Boxed warning, Warnings, Adverse reactions | Ticagrelor TICAGRELOR |
| BRILINTA | TICAGRELOR | Aphena Pharma Solutions - Tennessee, LLC | 1547e2b6-8858-178e-e063-6394a90abb23 | 2024-04-08 | Boxed warning, Warnings, Adverse reactions | TICAGRELOR |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents#
| Document | Submission type | Date |
|---|---|---|
| 55399 | ORIG | 2018-09-07 |